Switch theme
Sign up to access all valuation multiples
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
2009
19
LTM Revenue $0.4M
LTM EBITDA n/a
-$62.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Corbus Pharmaceuticals has a last 12-month revenue of $0.4M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Corbus Pharmaceuticals achieved revenue of n/a and an EBITDA of -$44.4M.
Corbus Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Corbus Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$33.3M | -$44.4M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$45.6M | -$42.3M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | $2.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 12, 2025, Corbus Pharmaceuticals's stock price is $7.
Corbus Pharmaceuticals has current market cap of $83.8M, and EV of -$62.0M.
See Corbus Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$62.0M | $83.8M | XXX | XXX | XXX | XXX | $-4.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 12, 2025, Corbus Pharmaceuticals has market cap of $83.8M and EV of -$62.0M.
Corbus Pharmaceuticals's trades at -159.4x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Corbus Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Corbus Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$62.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | 1.4x | XXX | XXX | XXX |
| P/E | -1.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 1.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCorbus Pharmaceuticals's NTM/LTM revenue growth is 564%
Corbus Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $2.4M for the same period.
Over next 12 months, Corbus Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Corbus Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Corbus Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 33% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $2.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Corbus Pharmaceuticals acquired XXX companies to date.
Last acquisition by Corbus Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Corbus Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Corbus Pharmaceuticals founded? | Corbus Pharmaceuticals was founded in 2009. |
| Where is Corbus Pharmaceuticals headquartered? | Corbus Pharmaceuticals is headquartered in United States of America. |
| How many employees does Corbus Pharmaceuticals have? | As of today, Corbus Pharmaceuticals has 19 employees. |
| Who is the CEO of Corbus Pharmaceuticals? | Corbus Pharmaceuticals's CEO is Dr. Yuval Cohen, PhD. |
| Is Corbus Pharmaceuticals publicy listed? | Yes, Corbus Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Corbus Pharmaceuticals? | Corbus Pharmaceuticals trades under CRBP ticker. |
| When did Corbus Pharmaceuticals go public? | Corbus Pharmaceuticals went public in 2014. |
| Who are competitors of Corbus Pharmaceuticals? | Similar companies to Corbus Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Corbus Pharmaceuticals? | Corbus Pharmaceuticals's current market cap is $83.8M |
| What is the current revenue of Corbus Pharmaceuticals? | Corbus Pharmaceuticals's last 12-month revenue is $0.4M. |
| What is the current EV/Revenue multiple of Corbus Pharmaceuticals? | Current revenue multiple of Corbus Pharmaceuticals is -159.4x. |
| Is Corbus Pharmaceuticals profitable? | Yes, Corbus Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
